Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bayer Aktienges ADR
(OP:
BAYRY
)
7.830
+0.060 (+0.77%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bayer Aktienges ADR
< Previous
1
2
3
4
5
6
Next >
7 Stocks Under $15 to Buy and Hold Forever
September 01, 2022
For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul.
Via
InvestorPlace
Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death
August 29, 2022
Via
Benzinga
Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops
August 29, 2022
The companies hoped to reduce the risk of myriad complications for at-risk patients.
Via
Investor's Business Daily
Bayer, Exscientia Part Ways On Artificial Intelligence Collaboration
August 18, 2022
Via
Benzinga
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
August 08, 2022
Via
Benzinga
This Biotech Says Stem Cells May Be Key To Freeing 65 Million Americans From Chronic Back Pain, Painkiller Dependence
July 27, 2022
BioRestorative Therapies Inc. (NASDAQ: BRTX), a stem cell-focused biotech, says it wants to shift the paradigm of how doctors treat chronic pain in hopes of giving patients an option that’s effective,...
Via
Benzinga
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
May 23, 2022
Via
Benzinga
Recap: Bayer Q4 Earnings
March 01, 2022
Bayer (OTC:BAYRY) reported its Q4 earnings results on Tuesday, March 1, 2022 at 01:30 AM. Here's what investors need to know about the announcement. Earnings Bayer beat...
Via
Benzinga
Why Is Ginkgo Bioworks (DNA) Stock in the Spotlight Today?
July 25, 2022
DNA stock is down even while Ginkgo Bioworks prepares to purchase a biotech business and a large research and development site.
Via
InvestorPlace
Science Wednesday: 'Silent Spring' At 60; Preserved Baby Mammoth Found In Yukon; Filling Medical Imaging, Nursing Shortages
June 29, 2022
(This marks the first installment of Benzinga’s new weekly series Science Wednesday, which provides an overview of news and milestones within the sciences.)
Via
Benzinga
BWXT Medical, Bayer Ink Commercial Agreement For Actinium-225 Based Products
June 27, 2022
Via
Benzinga
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
June 13, 2022
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week.
Via
Benzinga
7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend
June 08, 2022
These seven blue-chip stocks are trading at relative bargains and they can all be added to your portfolio for less than $250.
Via
InvestorPlace
Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off
June 01, 2022
Via
Benzinga
Three Stocks To Buy In This Bear Market
May 30, 2022
There’s a silver lining to the current bear market. It’s created great buying opportunities.
Via
Talk Markets
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
May 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
May 20, 2022
Via
Benzinga
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
May 19, 2022
As Keytruda's patent protection looms, will Merck be able to stanch the sales losses?
Via
Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
22nd Century Group Reports Q1 Net Sales Of $9M, Up 33% YoY, Net Loss Also Grows
May 05, 2022
22nd Century Group, Inc. (NASDAQ: XXII) reported results for the first quarter ended March 31, 2022.. The company will host a live audio webcast on May 5, at 10:00 a.m. ET.
Via
Benzinga
Investment Strategy Monthly Insights, April 2022
April 22, 2022
After four decades of low inflation, developed economies are grappling with an inflation spike.
Via
Talk Markets
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
April 21, 2022
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.
Via
Benzinga
Merck Projects $10 Billion From Its Next Blockbuster Segment; Will It Measure Up?
April 05, 2022
Merck shares hit a six-month high Tuesday on the bullish projection.
Via
Investor's Business Daily
What Stocks Do Well During a Bear Market? 7 Picks for a Downturn
March 16, 2022
These are the best bear market stocks to invest in now. T, BG and CL are some great picks for investors looking to weather the storm.
Via
InvestorPlace
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia
March 15, 2022
Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines."
Via
Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...
Via
Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
February 17, 2022
Can the formerly red-hot biotech segment return to its previous glory?
Via
Investor's Business Daily
Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer
February 15, 2022
Aveo Pharmaceuticals Inc (NASDAQ: AVEO) will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022...
Via
Benzinga
Why Are Evotec Shares Trading Lower On Friday?
February 04, 2022
Bayer AG (OTC: BAYRY) has
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.